Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Costs and Operating Expenses    
Research and development expenses, excluding depreciation $ 39,319 $ 19,293
Selling, general and administrative expenses, excluding depreciation 55,627 4,081
Depreciation 2,124 1,685
Total costs and operating expenses 97,070 25,059
Loss from operations (97,070) (25,059)
Other (expense) income    
Interest income (expense) 11 (5,825)
Gain on fair value change in contingent earnout shares liability 83,560  
Gain (loss) on fair value change in private placement warrants liability (1,639)  
Other expense, net (89) (6)
Loss before income taxes (15,227) (30,890)
Net loss and comprehensive loss $ (15,227) $ (30,890)
Per Share Data:    
Net loss per share, basic and diluted $ (0.07) $ (0.37)
Weighted-average shares outstanding, basic and diluted 224,795,000 82,444,000